Brent K. Larson

Brent K. Larson

Auto-generated profile, based on publicly available information

Brent K. Larson

Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 May 2020 in Cancers
Verified
Journal Article
Open access
PDF file
CGColleen Garvey
Colleen Garvey
RLRoy Lau
Roy Lau
ASAlyssa Sanchez
Alyssa Sanchez
RSRen X. Sun
Ren X. Sun
EFEmma J. Fong
Emma J. Fong
Shannon MumenthalerShannon Mumenthaler
Shannon Mumenthaler
Targeted agents have improved the efficacy of chemotherapy for cancer patients, however, there remains a lack of understanding of how these therapies affect the unsuspecting bystanders of the stromal microenvironment. Cetuximab, a monoclonal antibody therapy targeting the epidermal growth factor receptor (EGFR), is given in combination with chemotherapy as the standard of care for a subset of metastatic colorectal cancer patients. The overall response to this treatment is underwhelming and, while genetic mutations that confer resistance have been identified, it is still not known why this drug is ineffective for some patients. We discovered that cancer-associated fibroblasts (CAFs), a major cellular subset of the tumor stroma, can provide a source of cancer cell resistance. Specifically, we observed that upon treatment with cetuximab, CAFs increased their secretion of EGF, which was sufficient to render neighboring cancer cells resistant to cetuximab treatment through sustained mitogen-activated protein kinases (MAPK) signaling. Furthermore, we show the cetuximab-induced EGF secretion to be specific to CAFs and not to cancer cells or normal fibroblasts. Altogether, this work emphasizes the importance of the tumor microenvironment and considering the potential unintended consequences of therapeutically targeting cancer-driving proteins on non-tumorigenic cell types.

1 September 2018 in Pancreas
Verified
Journal Article
Closed access
BLBrent K. Do Larson
Brent K. Do Larson
RTRichard Tuli
Richard Tuli
LJLaith H. Jamil
Laith H. Jamil
SLSimon K. Lo
Simon K. Lo
NDNan Deng
Nan Deng
AHAndrew E. Hendifar
Andrew E. Hendifar
Objectives: Endoscopic ultrasound-guided fine-needle biopsy and aspiration (EUS FNB/A) are the standard diagnostic tests for pancreatic malignancies. Oncologists increasingly use tumor genomic analysis for management. Adequacy of FNB/A tissue for next-generation sequencing (NGS) has not been evaluated. This study examined FNB/A and other biopsy types for features that might predict adequacy for NGS. Methods: Seventy-six pancreatic exocrine malignancy biopsies submitted for NGS were assessed for adequacy, which was compared with other tumor/biopsy features. Results: Twenty-two (29%) of 76 samples were inadequate, including 16 (30%) of 54 FNBs and 4 (57%) of 7 FNAs. Larger-gauge needles were associated with adequacy in all samples (P = 0.0047) and in FNBs (P = 0.05). Metastatic samples were more likely to be adequate for NGS compared with pancreatic samples (P = 0.0357). Percutaneous biopsies were more likely to be adequate than EUS-guided FNB/As, although this trend was not significant (P = 0.0558). Other tumor/biopsy characteristics were not associated with adequacy. Conclusions: Endoscopic US FNA and FNB provided similar NGS adequacy rates. Metastatic lesions accessible by percutaneous biopsy may be preferable to EUS FNB/A of primary lesions for obtaining tissue for NGS. All biopsies, including EUS FNB, were more likely to be successful using larger-gauge needles.

1 July 2015 in Archives of Pathology & Laboratory Medicine
Verified
Journal Article
Closed access
BLBrent K. Larson
Brent K. Larson
DDDeepti Dhall
Deepti Dhall
Calcifying fibrous tumor is a benign mass lesion classically described as a soft tissue tumor. However, a thorough review of the literature reveals that it can occur virtually anywhere, including the tubular gastrointestinal (GI) tract. Its clinical manifestations are variable in the GI tract, and its imaging findings are nonspecific. However, it has unique histologic and immunophenotypical features that must be recognized by GI pathologists to differentiate it from an assortment of other rare mesenchymal lesions of the abdomen and GI tract. Calcifying fibrous tumor is composed of a paucicellular collagen matrix, interspersed calcified bodies, and a sparse inflammatory infiltrate. Although calcifying fibrous tumor is benign, pathologists must be aware that it may occur in the GI tract to differentiate it from other potentially more aggressive, rare mesenchymal lesions.

22 September 2014 in APMIS
Verified
Journal Article
Closed access
PDF file
BLBrent K. Larson
Brent K. Larson
BBBonnie Balzer
Bonnie Balzer
JGJerome Goldwasser
Jerome Goldwasser
DDDeepti Dhall
Deepti Dhall

2 August 2021 in Hepatic Oncology
Verified
Journal Article
Open access
MWMary Wong
Mary Wong
JKJong T Kim
Jong T Kim
BCBrian Cox
Brian Cox
BLBrent K Larson
Brent K Larson
SKStacey Kim
Stacey Kim
MGMaha Guindi
Maha Guindi
While researchers know that tumor mutational burden (TMB) is low in hepatocellular carcinoma (HCC), prior studies have not investigated TMB in cirrhosis, small early HCC and progressed HCC. HCC (n ...

28 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
YJYi Jiang
Yi Jiang
YAYazan Abboud
Yazan Abboud
JLJeff Liang
Jeff Liang
BLBrent Larson
Brent Larson
AOArsen Osipov
Arsen Osipov
SGSrinivas Gaddam
Srinivas Gaddam
In previous studies, a significant increase in the incidence of pancreatic cancer among younger women compared to men in the United States was noted. However, the specific histopathologic characteristics were not delineated. This population-based study aimed to assess whether this disproportionate rise in pancreatic cancer in younger women was contributed by pancreatic ductal adenocarcinoma (PDAC) or pancreatic neuroendocrine tumors (PanNET). The United States Cancer Statistics (USCS) database was used to identify patients with pancreatic cancer between 2001 and 2018. The results showed that, in younger adults, the incidence of PDAC has increased in women [average annual percentage change (AAPC) = 0.62%], while it has remained stable in men (AAPC = −0.09%). The PDAC incidence rate among women increased at a greater rate compared to men with a statistically significant difference in AAPC (p < 0.001), with neither identical nor parallel trends. In contrast, cases of PanNET did not demonstrate a statistically significant sex-specific AAPC difference. In conclusion, this study demonstrated that the dramatic increase in the incidence rate of PDAC explains the disproportionate rise in pancreatic cancer incidence in younger women. This prompts further prospective studies to investigate the underlying reasons for these sex-specific disparities in PDAC.